A pioneering leader in histone deacetylase inhibitors, focusing on largazole analogs for sickle cell disease

Cetya Therapeutics, Inc. is a Delaware C-Corporation based in Fort Collins, Colorado.  It was formed in 2012 to develop histone deacetylase inhibitors (HDACi) based on analogs of largazole.  HDAC inhibitors are approved for use in treatment of liquid tumors such as leukemias and lymphomas, but not for any solid tumor indication or an indication outside of oncology.  Cetya is focusing on sickle cell disease and has nominated a lead candidate compound, CT-101, for further development for treatment of that genetic disorder.